Aurobindo Pharma Limited (NSE:AUROPHARMA)

Market Cap	863.83B +26.9%
Revenue (ttm)	331.82B +7.3%
Net Income	34.87B -0.1%
EPS	60.04 +0.4%
Shares Out	580.80M
PE Ratio	24.77
Forward PE	20.42
Dividend	8.00 (0.54%)
Ex-Dividend Date	n/a

Volume	925,410
Average Volume	1,367,359
Open	1,487.30
Previous Close	1,487.30
Day's Range	1,477.40 - 1,505.50
52-Week Range	1,016.10 - 1,513.40
Beta	0.03
RSI	70.73
Earnings Date	May 30, 2026

About Aurobindo Pharma

Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretrovira...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1986
• Employees: 27,707
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: AUROPHARMA

Financial Performance

In fiscal year 2025, Aurobindo Pharma's revenue was 317.24 billion, an increase of 9.39% compared to the previous year's 290.02 billion. Earnings were 34.86 billion, an increase of 9.86%.